The HELIOS-B trial previously showed that vutrisiran (Amvuttra; Alnylam Pharmaceuticals), a gene-silencing therapy that ...

DONGGUAN, GUANGDONG, CHINA, January 13, 2026 /EINPresswire.com/ -- Globally, the medical industry is undergoing a major ...

A 76-year-old man from Gorakhpur found relief from chronic bronchitis through Patanjali's integrated treatment. The program ...

Researchers have discovered a biological switch that explains why movement keeps bones strong. The protein senses physical ...

DuBois, PA / Syndication Cloud / January 23, 2026 / Mercy Family Health Key Takeaways Direct-pay family medicine ...

Had she known the northwestern Quebec city of Val d’Or would be blanketed in snow in early November, Montrealer Anne Renaud ...

Ageism is prejudice directed toward someone based on their age, particularly older people, and it persists among clinicians ...

Budget boosts support for differently abled and elderly, increasing allocations for care homes and financial assistance.

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of ...

Approved as Quviviq in Japan, daridorexant is being marketed through a partnership between Nxera and Shionogi.

Did you know that there are over 7.6 million job openings in the United States alone, with many companies grasping at straws ...

Approximately 30% of Sri Lanka’s adult population suffers from mental health issues, Consultant Psychiatrist Dr ...